Recent Updates
Recently added Catalysts
ARGX Positive Sentiment

argenx Announces Results of Extraordinary General Meeting of Shareholders

Tuesday, November 18, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: argenx SE announced the results of its Extraordinary General Meeting held on November 18, 2025. The sole agenda item, a remuneration policy, was overwhelmingly approved by shareholders with 95.67% voting in favor. Additionally, 91.1% of the company's share capital participated in the voting, reflecting strong support for the company's governance.
Price reaction · baseline $929.61 (2025-11-17 close) · hit after-hours · clean, no other ARGX news in the window
day 0 close · peak
-1.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Approval of the remuneration policy by a significant majority (95.67%)
  • High level of shareholder participation with 91.1% of share capital represented
  • Demonstrates strong shareholder support and company governance

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+36%
120-day peak, hindsight
Typical move
4.7%
average across 12 past catalysts
Lead asset
Empasiprubart
Phase 2 · AChR-Ab Seropositive Generalized Myasthenia Gravis

Full Press Release Details

argenx Announces Results of Extraordinary General Meeting of Shareholders
November 18, 2025 - 10:01 PM CET
Amsterdam, the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Extraordinary General Meeting of shareholders held on November 18, 2025.
The remuneration policy, which was the sole voting item on the agenda, was approved by the required majority of votes. The Company's remuneration policy was approved by a 95.67% majority, with 91.1% of share capital represented at the Extraordinary General Meeting.
The voting result and all documents relating to the shareholders' meeting will be available on the argenx website at www.argenx.com/investors/shareholder-meetings .
For further information, please contact:

Frequently Asked Questions

When was the Extraordinary General Meeting held?

The Extraordinary General Meeting took place on November 18, 2025.

What was the main agenda item for the meeting?

The sole agenda item was the approval of the remuneration policy.

What percentage approved the remuneration policy?

The remuneration policy was approved by 95.67% of votes.

How much share capital was represented at the meeting?

A total of 91.1% of share capital was represented at the meeting.

Where can I find the meeting documents?

Meeting documents are available on the argenx website under investor relations.

ShareAdd on Google
Tags: ARGX Viatris Investor Conferences Healthcare argenx shareholder meeting remuneration policy Amsterdam
Last updated: Nov 18, 2025

Biotech snapshot

Lead asset
EmpasiprubartPhase 2
AChR-Ab Seropositive Generalized Myasthenia Gravis →

Catalyst track record

+36%
best trade around ARGX's most recent catalyst

Peak hindsight return over a 120-day window, across 12 tracked FDA/PDUFA catalysts for ARGX.

See every catalyst's timing & PoA →